TGFB1 and non-small cell lung carcinoma: Second, the interpretation of our findings may be constrained, since previous studies evaluating the prognostic impact of TGF-β in NSCLC usually refer to plasma levels of TGF-β, whereas those that are investigating its possible therapeutic activity with inhibitors do not reflect data on TGF-β expression in treated patients.